For those of you who follow our podcast elsewhere, you may notice that this interview was from last month. We’re excited to finally get this episode on UA-cam, and, for those of you in the US, hope you have a great long weekend!
*PLEASE* for the love of science, put "Podcast" in the title so I can skip these when that's not what I'm looking for. "Surprise podcast" is not a fun game
As a young guy who has gone through both an autologous and an allogeneic stem cell transplant for multiple myeloma, I found this very interesting. I'm currently on a maintenance treatment and doing pretty well but previously had a bad reaction to a clinical trial of a different maintenance treatment, so I knew a lot of the stuff talked about in this but still interesting. BTW, myeloma is misspelled in the first sentence of the description.
Aaron, great interview! I took a course in pathophysiology while training to become a biostatistician, but we didn't have time to dig into a lot of details. You asked a lot of follow-up questions digging into the technical specifics of how multiple myleoma works and what is involved in the various treatments - I learned a lot! The possibilities with CAR T cell therapy are intriguing. I'd love to work in that area of research. That story about the patient in treatment leading the cyclists at the end got me right in the feelings!
Having had AML (Acute Myeloid Leukemia), including an allogenic transplant, a lot of what was discussed is quite familiar. I do NOT miss bone marrow biopsies. It is fun to say I'm a chimera, though...and that my blood type changed.
Some of the newest research on Multiple Myleloma is focused on making off-the-shelf allogenic CAR-T cells that dodge host vs graft disease. This will be significantly cheaper and easier than using patient derived cells. Source - I work for one of the companies doing this.
For those of you who follow our podcast elsewhere, you may notice that this interview was from last month. We’re excited to finally get this episode on UA-cam, and, for those of you in the US, hope you have a great long weekend!
I just realized I've missed almost all of the podcasts assuming they'd be on UA-cam as well. >.>
*PLEASE* for the love of science, put "Podcast" in the title so I can skip these when that's not what I'm looking for.
"Surprise podcast" is not a fun game
Great informative interview. My wife was Dx in late 1989 at Methodist (IU). This Dec we'll celebrate 30 years!
Hey I just wanted to say how informative and helpful this podcast was for me!
Wow I lost my Grandpa on Sunday after a long battle with Multiple Myeloma. I hope they find a cure, so no one has to go through the pain he suffered.
great podcast right here. thanks again.
As a young guy who has gone through both an autologous and an allogeneic stem cell transplant for multiple myeloma, I found this very interesting. I'm currently on a maintenance treatment and doing pretty well but previously had a bad reaction to a clinical trial of a different maintenance treatment, so I knew a lot of the stuff talked about in this but still interesting.
BTW, myeloma is misspelled in the first sentence of the description.
Aaron, great interview! I took a course in pathophysiology while training to become a biostatistician, but we didn't have time to dig into a lot of details. You asked a lot of follow-up questions digging into the technical specifics of how multiple myleoma works and what is involved in the various treatments - I learned a lot! The possibilities with CAR T cell therapy are intriguing. I'd love to work in that area of research. That story about the patient in treatment leading the cyclists at the end got me right in the feelings!
Having had AML (Acute Myeloid Leukemia), including an allogenic transplant, a lot of what was discussed is quite familiar. I do NOT miss bone marrow biopsies. It is fun to say I'm a chimera, though...and that my blood type changed.
Looking for trials.had bone marrow transplant in jan20,2016
Some of the newest research on Multiple Myleloma is focused on making off-the-shelf allogenic CAR-T cells that dodge host vs graft disease. This will be significantly cheaper and easier than using patient derived cells. Source - I work for one of the companies doing this.
amazing
Very informative